May 30, 2019 - Bio Pharma Dive
Vibalogics and Ampersand Capital Partners didn't disclose deal terms in a May 29 release, but the acquisition does bring 50 employees and a 27,000-square-foot manufacturing facility in Cuxhaven, Germany.
May 30, 2019 - Fierce Pharma
Cantor Fitzgerald analyst Louise Chen and her team made that comment in a Tuesday note to investors. Their reason? The Pfizer treatment's lower cost compared with its eventual rivals, for one thing. But, more important is a large population of patients with ATTR cardiomyopathy—1 million in the U.S. alone—that may be largely untapped now, but probably won't remain so for long.
May 28, 2019 - Fierce Biotech
Eli Lilly is paying $47.5 million upfront to
license
Centrexion Therapeutics’ phase 1 non-opioid pain drug. As the Big Pharma works on the program, Centrexion stands to net up to $575 million in development and regulatory milestones as well as another $375 million if the drug makes it to market.
May 28, 2019 - Fierce Biotech
Acquisitive Icon is at it again as it snaps up a majority stake in British site network company MeDiNova Research with an option to buy out the remaining shares penned into the deal.
May 28, 2019 - Fierce Pharma
Novartis’ promise of 25 potential blockbuster launches is steadily coming to fruition. On the same day the FDA approved gene therapy Zolgensma, the U.S. regulator also waved through breast cancer drug Piqray.
